AGP Executive Report
Last update: 9 hours agoRett syndrome treatment: Acadia’s DAYBU® (trofinetide) won a positive CHMP opinion in the EU for neurobehavioral symptoms in adults and children aged five and up—next step is an EC marketing authorization, with support from the Phase 3 LAVENDER study. Bladder cancer care: Merck/MSD’s KEYTRUDA + Padcev combo (pembrolizumab + enfortumab vedotin) secured EU approval as perioperative treatment for resectable muscle-invasive bladder cancer in adults who can’t receive cisplatin, based on KEYNOTE-905/EV-303 results. Breast cancer option: Gilead’s Trodelvy® (sacituzumab govitecan) gained EC approval in the EU as first-line monotherapy for unresectable or metastatic triple-negative breast cancer patients not eligible for PD-1/PD-L1 therapy. Heat and schools: A Europe-wide heatwave is forcing schools to close or shorten days, with limited cooling in many classrooms raising concerns for child health. Travel health rules: UK authorities warn holidaymakers returning from the EU not to bring banned meat and dairy items to avoid fines and confiscation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
